Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Sanders

Physician Assistant, Medical Rock Springs, WY Physician Assistant

NPI 1619018918 CMS profile 1120961

1200 College Dr, Rock Springs, WY 82901

Open in the dashboard

General payments

$5,083

258 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Sanders of Rock Springs, WY is reported in the CMS Open Payments database as having received $5,083 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,139 60
2024 General $927 39
2023 General $918 41
2022 General $1,105 56
2021 General $994 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Sanders
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mark Sanders were reported at $1,139. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mark Sanders Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $994 $156 $41–$563 $132
2022 $1,105 $185 $55–$649 $149
2023 $918 $199 $58–$717 $160
2024 $927 $206 $62–$740 $164
2025 $1,139 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,086 38 payments
  2. AbbVie, Inc. $980 41 payments
  3. Lilly USA, LLC $370 30 payments
  4. Amgen Inc. $350 21 payments
  5. Merck Sharp & Dohme Corporation $293 18 payments
  6. GlaxoSmithKline, LLC. $262 13 payments
  7. Otsuka America Pharmaceutical, Inc. $219 13 payments
  8. Corium, Inc. $214 9 payments
  9. Lundbeck LLC $164 8 payments
  10. Pfizer Inc. $155 9 payments
  11. Other $989 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,034 253 payments
  2. Education $49 5 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $830 25 payments
  2. BREZTRI $688 17 payments
  3. UBRELVY $605 24 payments
  4. VRAYLAR $316 14 payments
  5. AIRSUPRA $270 3 payments
  6. VERQUVO $260 14 payments
  7. TRELEGY ELLIPTA $244 12 payments
  8. REXULTI $219 13 payments
  9. Azstarys $214 9 payments
  10. MOUNJARO $208 18 payments
  11. Other $3,390 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

5,621

Median for Physician Assistant: 241

Drug cost

$552,295

Median for Physician Assistant: $4,110

Branded share of claims

25.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 118 $85,042
Xarelto Rivaroxaban Brand 52 $54,136
Farxiga Dapagliflozin Propanediol Brand 26 $36,093
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 28 $32,510
Janumet Sitagliptin Phos/Metformin Hcl Brand 19 $30,817
Jardiance Empagliflozin Brand 19 $26,254
Ozempic Semaglutide Brand 21 $25,577
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $25,232
Synjardy Empagliflozin/Metformin Hcl Brand 16 $23,947
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $17,698

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$68,289

Of which drugs: $3,065

Medicare patients

534

Average age 72

Services billed

1,499

277 women, 257 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 30%
Diabetes 22%
COPD 19%
Ischemic heart disease 18%
Atrial fibrillation 14%
Chronic kidney disease 13%
Heart failure 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $74
  • Otsuka America Pharmaceutical, Inc. $38
$112 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $96
$96 28 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $90
$90 26 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $78
$78 26 —
YUPELRI
  • Mylan Specialty L.P. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record